ImmunityBio's ANKTIVA Shows Promise in Bladder Cancer Despite Stock Decline
ImmunityBio's ANKTIVA demonstrates a 71% complete response rate in bladder cancer trials, but the company's stock falls 7.25%.
ImmunityBio's ANKTIVA demonstrates a 71% complete response rate in bladder cancer trials, but the company's stock falls 7.25%. This is an original TLT brief based on reporting by Blockonomi, with live market data added, as of Fri, 16 Oct 2026 21:00:03 UTC.
The development is significant as it highlights a potential breakthrough in bladder cancer treatment, with impressive response rates and long-lasting effects, which could transform treatment options and improve patient outcomes.
- ANKTIVA shows 71% complete response rate in bladder cancer trial.
- Median response duration is 26.6 months, with some exceeding 53 months.
- 84% of responding patients remain cystectomy-free after three years.
- FDA expands ANKTIVA's use based on trial data.
ImmunityBio's ANKTIVA has shown promising results in a 100-patient bladder cancer trial, with a complete response rate of 71%, as reported by multiple outlets. The treatment has demonstrated a median response duration of 26.6 months, with some responses lasting beyond 53 months.
The trial's three-year data indicates that 84% of patients who responded to ANKTIVA remain cystectomy-free, underscoring the treatment's potential to significantly improve patient outcomes. These findings have led to the FDA expanding ANKTIVA's use, as reported by Blockonomi.
Despite the positive trial results, ImmunityBio's stock has experienced a decline, falling 7.25% to $9.27. This suggests that while the clinical data is promising, market reactions may be influenced by other factors.
The broader market context shows a relatively flat overall market, with a total crypto market cap of $2.8 trillion. 
Bitcoin has seen a 0.98% decrease in the last 24 hours, and the Fear & Greed index stands at 63, indicating a state of 'Greed' among investors.
The development of ANKTIVA in bladder cancer treatment could have significant implications for the future of oncology therapies. Investors and stakeholders will likely monitor further clinical outcomes and regulatory approvals to assess the long-term impact on ImmunityBio's market position.
ImmunityBio's ANKTIVA Shows Promise in Bladder Cancer De — questions & answers
What is the complete response rate for ANKTIVA in bladder cancer trials?
ANKTIVA has achieved a 71% complete response rate in a 100-patient bladder cancer trial.
How long do the responses to ANKTIVA last?
The median response duration is 26.6 months, with some responses exceeding 53 months.
What is the three-year cystectomy-free survival rate for responding patients?
84% of responding patients remain cystectomy-free after three years.
Which outlets reported this story?
This is an original TLT brief that synthesises reporting from Blockonomi. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original TLT brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.